Old name, new purpose: why we’ve gone back to RNID

  1. Home
  2. News and stories
  3. The global hearing research community is invited to join the 2023 Hearing Therapeutics Summit

The global hearing research community is invited to join the 2023 Hearing Therapeutics Summit

RNID is delighted to join forces with the University College London Ear Institute and National Institute of Health Research to run the 2023 Hearing Therapeutics Summit on 2 September.

The theme of this year’s summit is ‘connecting academia and industry to accelerate hearing therapeutics’. The event will bring together the international hearing research community – hearing researchers, clinical scientists, biotech, pharma and hearing device companies, research funders and investors – to explore the development of inner ear therapeutics over talks and networking sessions.  

Join the waiting list

Registration for the 2023 Hearing Therapeutics Summit is now closed. To be notified as additional places become available, please register your interest below.
Join the waiting list

This one-day event on 2 September will be followed by the 58th Inner Ear Biology Workshop on the 3-5 September. 

Who is attending

An all star line up of international speakers will present their thoughts, insights and lessons, learned from their pioneering work in bringing new treatments for hearing loss out of the lab and into the clinic. Speakers include key opinion leaders from Fennec Pharma, Rinri Therapeutics, Acousia Therapeutics, Jobral Consulting, CILcare, Oricula Therapeutics, and King’s College London.  

We’re excited to unveil the day’s final schedule below.

The HTI summit programme of events

12:40-12:45 Welcome – Dr Ralph Holme (RNID, UK) 

12:45-13:00 ‘My experience of deafness’ – Hugh Strickland (Aaron & Partners Solicitors, UK) 

13:00-14:15 Session 1

Bringing new treatments to the clinic – lessons learned along the way, chaired by Prof Anne Schilder (NIHR UCLH BRC, UK): 

  • 13:00-13:15 ‘Drug discovery and development challenges in hearing disorders’ – Dr Alan C Foster (Jobral Consulting, USA) 
  • 13:15-13:30 ‘ACOU085 – lessons learned from developing a locally administered otoprotectant’ – Dr Jonas Dhyrfjeld-Johnsen (Acousia Therapeutics, Germany)
  • 13:30-13:45 ‘PEDMARK® (sodium thiosulfate injection): approved for reduction of risk of ototoxicity associated with cisplatin in pediatric population with localized, non-metastatic solid tumors’  – Mr Jeremy DiCandilo (Fennec Pharmaceuticals, USA) 
  • 13:45-14:15 Speakers panel discussion and audience Q&A  

14:15-15:00 Coffee and networking

15:00-15:15 ‘The Hearing Therapeutics Initiative’ – Dr Catherine Perrodin (RNID, UK) 

15:15-16:15 Session 2

Basic science to the rescue – open challenges in hearing therapeutics development, chaired by Prof Jonathan Gale (UCL Ear Institute): 

  • 15:15-15:30 ‘Hearing in background noise: the path toward future treatments using digital evaluation’ – Dr Gaëlle Naert (CILcare, France) 
  • 15:30-15:45 ‘Segmenting the biological causes of hearing loss’ – Prof Karen P Steel (King’s College London, UK) 
  • 15:45-16:00 ´ORC-13661: from fish tank to first-in-class drug’ – Prof David W Raible (Oricula Therapeutics, USA) 
  • 16:00-16:15 Speakers panel discussion and audience Q&A  

16:15-17:00 Fireside chat: Bridging the gap between academia and industry, Dr Simon Chandler and Prof Marcelo Rivolta (Rinri Therapeutics, UK) in conversation with Dr Barbara Domayne-Hayman (Autifony/Francis Crick Institute, UK)

17:00-17:05 Closing remarks with Prof Jonathan Gale

17:00-19:00 Networking session & drinks reception 

More like this

Back to top